[Alpha fetoprotein in XXXX before and during treatment].

@entity1 @entity1375 @entity1087 @entity648 @entity2016 @entity6750
BACKGROUND: Screening for @entity6750 ( @entity6750 ) is an opportunity to investigate maturation by measuring alphafetoprotein (AFP). @entity1 AND METHODS: Blood AFP was measured in 73 full-term @entity1 (controls), 22 @entity1 with permanent @entity6750 and 19 with a transient form (FT) of @entity1375 . It was also measured in mothers of the two groups with @entity1375 . AFP was measured by RIA and its value was compared to those of FT4, TSH and @entity648 . RESULTS: Blood AFP was higher in @entity1 with @entity6750 with significant differences between @entity1 who had @entity1087 or not, but AFP was not significantly different in FT @entity1 and controls. Initial values of AFP in both @entity6750 and FT population was correlated to the levels of AFP in their mothers. Under treatment with 7.5 micrograms/kg/day of @entity2016 , AFP levels remained increased at T15, then gradually normalized at T30-T60. The log of AFP was correlated to TSH levels between T15 and T60 but was not correlated to FT4 levels. Preliminary results at one year of age show that IQ seems better in @entity1 with early normalization of AFP. CONCLUSIONS: Prolonged follow-up is necessary to assess the possibility that initial kinetics of AFP under therapy have a prognostic value for estimating the quality of outcome.
